Výsledky vyhledávání - "Joanna Van Elk"

AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 21:S290

Context: Magrolimab, an anti-CD47 antibody, induces tumor phagocytosis and eliminates leukemia stem cells. Azacitidine (AZA) synergizes with magrolimab by inducing prophagocytic “eat me” signals. Magrolimab + AZA is clinically effective in acute

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::36c280f3cd4ef68bafb95d2d7eb8be3c
https://doi.org/10.1016/s2152-2650(21)01694-3

Zobrazit plný text záznamu

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results

Autor: Chris H. Takimoto, William B. Donnellan, Terrence Bradley, David A. Sallman, Roy Louis Maute, Mark P. Chao, Monzr M. Al Malki, Rami S. Komrokji, Suman Kambhampati, Daniel Junseung Lee, Ming Lin, Jens-Peter Volkmer, Adam S. Asch, Guido Marcucci, Deepa Jeyakumar, Joanna Van Elk, Paresh Vyas, Naval Daver

Publikováno v: Journal of Clinical Oncology. 38:7507-7507

7507 Background: Magrolimab (Hu5F9-G4) is an antibody blocking CD47, a macrophage immune checkpoint and don’t eat me signal on cancers. It induces tumor phagocytosis and eliminates leukemia stem cells. Azacitidine (AZA) synergizes with magrolimab b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ee54c9d26b936ce33eb32c2857d9d6e3
https://doi.org/10.1200/jco.2020.38.15_suppl.7507

Zobrazit plný text záznamu

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

Autor: Naval Daver, Jens-Peter Volkmer, Mark P. Chao, Guillermo Garcia-Manero, Suman Kambhampati, Rami S. Komrokji, Daniel J. Lee, Guido Marcucci, Chris H. Takimoto, Adam S. Asch, David A. Sallman, Monzr M. Al Malki, William B. Donnellan, Paresh Vyas, Joanna Van Elk, Ming Lin

Publikováno v: Blood. 134:569-569

Background Magrolimab (previously named 5F9) is a first-in-class antibody targeting CD47, a macrophage immune checkpoint and "don't eat me" signal on cancers. CD47 blockade induces tumor phagocytosis and eliminates leukemia stem cells (LSC) in AML mo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::01a93e17a663694d07d637e9901106eb
https://doi.org/10.1182/blood-2019-126271

Zobrazit plný text záznamu

The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results

Autor: William B. Donnellan, Chris H. Takimoto, Jens-Peter Volkmer, Rami S. Komrokji, David A. Sallman, Ming Lin, Daniel Junseung Lee, Balaji Agoram, Suman Kambhampati, James Y. Chen, Monzr M. Al Malki, Mark P. Chao, Paresh Vyas, Adam S. Asch, Guido Marcucci, Joanna Van Elk, Daniel A. Pollyea

Publikováno v: Journal of Clinical Oncology. 37:7009-7009

7009 Background: Hu5F9-G4 (5F9) is an antibody targeting CD47, a macrophage immune checkpoint and “don’t eat me” signal on cancers. CD47 blockade induces tumor phagocytosis and eliminates leukemia stem cells (LSC) in AML models. Azacitidine (AZ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7987bddd8d9d6142ddea6ac5c7756feb
https://doi.org/10.1200/jco.2019.37.15_suppl.7009

Zobrazit plný text záznamu

Clinical and immunologic evaluation of HIV-infected patients treated with dinitrochlorobenzene

Autor: Billi Goldberg, Raphael B. Stricker, Cecilio Dumlao, Blaine F. Elswood, Jim Henry, William L. Epstein, Joanna Van Elk, Edward E. Winger

Publikováno v: Journal of the American Academy of Dermatology. 31:462-466

Background: Promotion of cell-mediated immunity appears to be an important goal in the control of HIV infection. Topical dinitrochlorobenzene (DNCB) stimulates systemic cell-mediated immunity via the induction of cutaneous delayed-type hypersensitivi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef4fa2703cc884ac17e39013c92bdd85
https://doi.org/10.1016/s0190-9622(94)70212-8

Zobrazit plný text záznamu

Pilot study of topical dinitrochlorobenzene (DNCB) in human immunodeficiency virus infection

Autor: Jordan W. Tappero, Joanna Van Elk, Blaine F. Elswood, Timothy G. Berger, Raphael B. Stricker, Cecilio Dumlao, Dobri D. Kiprov, Yu Sheng Zhu, William L. Epstein

Publikováno v: Immunology letters. 36(1)

Dendritic cells, the primary antigen presenting cells of the human immune system, are heavily infected with human immunodeficiency virus (HIV) in patients with the acquired immunodeficiency syndrome (AIDS). Dinitrochlorobenzene (DNCB) is a contact se

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2acbcdc060254dfae51dec2d71588b26
https://pubmed.ncbi.nlm.nih.gov/8102123

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání